Hologic and Vossius take action against Siemens Healthineers over mammography system
The UPC's Düsseldorf local division has issued a sales ban against Siemens Healthineers' MAMMOMAT B.brilliant mammography system in Germany, France, and the Netherlands, following a patent infringement lawsuit filed by Hologic. The dispute centers on Hologic's EP 2 352 431 patent, which covers technology designed to prevent image blurring during mammography. Siemens Healthineers has announced an appeal against the ruling, which also dismissed its counterclaim for revocation and prior use rights.
Hologic stock leans on diagnostics and imaging
Hologic, a Nasdaq-listed medical technology company, primarily focuses on women's health, diagnostics, and breast-health systems. The company's business model relies on recurring testing and installed-base equipment, with its diagnostics franchise and breast-health products being key drivers. Hologic's stock performance is linked to procedure volume and consumables demand, operating within the U.S. healthcare and med-tech peer set.
Hologic removes BioZorb 3D bioabsorbable markers due to safety reasons
Hologic, Inc. is recalling its BioZorb Marker due to a significant number of reported complications and adverse events, including pain, infection, and device migration, though no deaths have occurred. The implantable radiographic marker, used to identify soft tissues like breast tissue for medical procedures, consists of both permanent titanium and resorbable plastic components. The recall comes after 252 reported injuries were linked to the device.
FDA updates Hologic BioZorb recall, citing 252 injuries
The FDA reported 252 injuries linked to Hologic’s BioZorb radiographic markers, almost two years after Hologic instructed customers to stop using the devices due to adverse events. While the company no longer manufactures these markers, healthcare providers are advised to monitor patients with implants for issues such as pain, infection, or device migration, though removal is not recommended. This update follows a warning letter the FDA issued to Hologic in December 2025 for failing to meet design requirements for the markers.
Ascendis drug data show leg alignment kept improving through 2 years
Ascendis Pharma reported positive Week 104 data from its pivotal ApproaCH trial for TransCon CNP in children with achondroplasia. The data showed continued improvements in lower extremity alignment, specifically tibial-femoral angle (TFA) and TFA Z-scores, over two years, with greater improvements in children with pre-existing genu varum. The treatment was generally well-tolerated, reinforcing its potential as a pharmacological treatment for achondroplasia.
Research Supports Hologic’s AI-Powered Mammography Tech for Detecting Challenging Cancers
New research validates Hologic's AI-driven mammography technology, Genius AI Detection, for effectively identifying invasive lobular cancers, which are often challenging to detect. A study by Massachusetts General Hospital found the AI solution correctly localized nearly 90% of confirmed invasive lobular cancers, including 43% initially missed by standard screenings. This indicates the strong potential for AI to support radiologists in detecting diverse breast cancer subtypes, improving early diagnosis for these difficult-to-spot cancers.
Wingstop (WING) Has a Unit-Economics and Expansion Engine Bigger Than a Chicken-Demand Narrative
Wingstop's business model is primarily an asset-light franchisor, not solely dependent on chicken prices or consumer demand. The company's strong unit economics are driven by high digital penetration, consistent new unit development, and a large whitespace opportunity for growth. Despite fluctuations in same-store sales or commodity costs, Wingstop's robust franchising model and capital allocation through dividends and share repurchases contribute to its durable earnings power.
How HIV Testing Powers Prevention, Treatment and Hope
HIV testing is crucial for prevention, treatment, and ending the epidemic, despite significant progress turning HIV from a fatal diagnosis into a manageable chronic condition. Disparities in access and continued stigma hinder universal testing and care, particularly in marginalized populations. Innovations in testing and long-acting preventive treatments like PrEP depend on routine and accurate HIV testing to be effective, supporting global goals to achieve viral suppression and end the AIDS epidemic by 2030.
Mireille Akilian on Women’s Health & GYN Surgical Innovation
Mireille Akilian, VP of R&D for Surgical Solutions at Hologic, discusses advancing technologies for gynecologic conditions like abnormal uterine bleeding and uterine fibroids. She emphasizes the importance of integrating quality into innovation, improving imaging in hysteroscopy, and the potential role of AI in streamlining procedures and enhancing diagnostic accuracy. Akilian envisions a future where women can be diagnosed and treated for these conditions in a single, accessible visit.
Exosomes Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO
The article details the Exosomes Pipeline in 2026, highlighting over 80 companies developing more than 100 exosome treatment therapies, as per DelveInsight's report. It covers emerging therapies in various clinical trial phases, recent advancements such as NurExone's spinal cord injury trials and Capricor Therapeutics' vaccine platform, and key companies in the exosome therapeutics market. The report also addresses market drivers like the growing interest in cell-free therapies and challenges such as standardization and regulatory uncertainty.
Le nouveau Rapport de durabilité d’Hologic célèbre 40 ans de réalisations
Hologic, Inc. has published its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's commitment to improving women's health globally and details significant progress in environmental goals, including reducing operational emissions and water usage, and increasing renewable energy reliance. Hologic's initiatives have impacted over 199 million lives in 2025 through its women's health solutions and community engagement efforts.
Hologic Inc (HOLX) Valuation: PE, PB & Fair Value Analysis
Hologic Inc (HOLX) currently holds a valuation score of 6.84, ranking 143 out of 208 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is 31.32, which is below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Canaccord Genuity Sticks to Its Buy Rating for Newell Brands (NWL)
Canaccord Genuity analyst Brian McNamara has reiterated a Buy rating for Newell Brands (NWL) with a price target of $9.00. While the company reported a slight revenue decrease and a GAAP net loss in its latest quarter, the analyst's outlook remains positive. However, corporate insider sentiment for NWL stock is negative, with an increase in insider selling over the past quarter.
Hologic Inc (HOLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Hologic Inc (HOLX), detailing its current price momentum score, identified support and resistance levels, and a comprehensive breakdown of various technical indicators and moving averages. The analysis suggests the stock is currently suitable for range-bound swing trading, with a majority of indicators and all moving averages signaling a "Buy."
Twin Securities, Inc.'s Hologic Inc(HOLX) Holding History
This article details Twin Securities, Inc.'s historical holdings in Hologic Inc (HOLX). As of March 31, 2026, Twin Securities holds 179,036 shares valued at $13.53 million, representing 6.57% of their portfolio. The firm has an estimated gain of 2.40% on their HOLX holdings, having initiated the position in Q4 2025 with an average purchase price of $74.23.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic, a global leader in women's health, released its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's progress in reducing environmental impact, advancing health equity, and fostering an engaged workforce, aligning with its mission to improve women's health worldwide. Key achievements include impacting over 199 million lives, committing to net-zero emissions by 2050, and achieving high employee engagement.
Hologic Inc (HOLX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Hologic Inc (HOLX) has an earnings forecast score of 6.00, ranking it 176 out of 208 in its industry. Analysts have set an average price target of $76.00 for HOLX, with a high of $79.00 and a low of $70.00. The company's expected revenue for the next quarter is $1.03 billion, and its EPS for the previous quarter was $0.83, exceeding the market expectation of $0.80.
Needles used to detect breast cancer in shortage from recall
The U.S. is facing a shortage of breast biopsy needles due to a recall by Hologic Inc. earlier this year, which could delay breast cancer diagnoses. The shortage, expected to last until March 2027, stems from reports of metal and plastic pieces dislodging from the needles and remaining in patients. This issue is causing significant challenges for breast imaging practices and carries risks such as infection and diagnostic delays.
Hologic Inc (HOLX) Institutional Confidence
This article provides an "Institutional Confidence" overview for Hologic Inc (HOLX), detailing current stock information, market capitalization, and P/E TTM. It highlights a table of institutional shareholders with their shares held and percentage changes, noting the institutional confidence score and its changes. The data was last updated on April 6, 2026.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic, Inc. has released its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's efforts to reduce environmental impact, advance health equity for women, and engage its purpose-driven workforce. Key achievements include impacting over 199 million lives through women's health solutions, getting climate targets validated by SBTi, and reducing operational emissions by 27%.
Hologic wins patent case against Siemens Healthineers over mammo technology
Hologic has won a patent infringement case against Siemens Healthineers concerning breast tomosynthesis imaging technology. The Unified Patent Court’s Düsseldorf Local Division ruled largely in favor of Hologic, finding that Siemens Healthineers’ MAMMOMAT B.brilliant mammography platform infringed Hologic's European Patent EP 2 352 431 B1. Siemens Healthineers has 60 days to comply with the decision or appeal it, which could lead to an injunction preventing sales and marketing of the infringing product in Germany, France, and the Netherlands.
Needles Used to Detect Breast Cancer in Shortage From Recall
The FDA has announced a shortage of breast biopsy needles in the U.S. following a recall by Hologic Inc. This shortage could lead to delays in breast cancer diagnosis, as the issue is projected to persist until March 2027. Doctors are advised to conserve their current supply of needles.
Hologic Inc (HOLX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Hologic Inc (HOLX), listing its major shareholders and their respective proportions, along with a breakdown of shareholder types such as investment advisors and hedge funds. It also provides institutional shareholding data over several quarters and recent shareholder activity of key institutions.
Hologic Wins Patent Battle Against Siemens Healthineers, Orders Mammography System Recall
Hologic secured a victory in the Unified Patent Court (UPC) in Germany against Siemens Healthineers for patent infringement. The court ruled that Siemens infringed on Hologic's Focusing Technology on the Envision platform with its Mammomat B.brilliant systems. As a result, Siemens has been ordered to immediately cease making and selling the infringing systems in Germany, France, and the Netherlands, and must also conduct a mandatory recall and destruction of all affected systems in those countries.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic, a global leader in women's health, has released its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's progress in environmental sustainability, women's health initiatives, employee engagement, and responsible business practices. Key achievements include impacting over 199 million lives, validating expanded climate targets with SBTi, and reducing operational emissions by 27%.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic, a global leader in women's health, released its 2025 Sustainability Report, coinciding with its 40th anniversary. The report highlights the company's commitment to enabling healthier lives for women and details progress in environmental sustainability, employee engagement, community support, and responsible business practices. Hologic's Chief Sustainability Officer, Sharon Vidal, emphasized the company's belief that its success is tied to empowering women's health worldwide.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic has released a new sustainability report, coinciding with the company's 40th anniversary. This report highlights Hologic's long-standing impact in areas such as women's health and technology, reinforcing its commitment to sustainability. The article mentions various related topics like global women's health issues and other companies' sustainability reports.
Hologic’s New Sustainability Report Marks 40 Years of Impact
Hologic, Inc. has released its 2025 Sustainability Report, coinciding with the company's 40th anniversary. The report highlights progress in reducing environmental impact, advancing health equity, and engaging a purpose-driven workforce, impacting over 199 million people in 2025 through its women's health solutions. Hologic also committed to significant climate targets, aiming to cut emissions by half by 2030 and achieve net-zero by 2050, while showcasing strong employee engagement.
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology
Hologic has achieved a significant patent victory against Siemens concerning breast cancer detection technology. This news, reported by Refinitiv via Reuters, indicates a legal triumph for Hologic in a key area of medical diagnostics. The victory underscores the importance of intellectual property in the competitive healthcare technology sector.
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology
Hologic, Inc. announced a significant patent victory against Siemens in the Unified Patent Court (UPC) in Germany concerning breast cancer detection technology. The court ruled that Siemens infringed on a critical Hologic mammography patent, ordering Siemens to halt production, recall, and destroy affected MAMMOMAT B.brilliant systems in Germany, France, and the Netherlands. Hologic will also receive monetary damages and costs, and Siemens must refund customers for the infringing systems.
Fresenius Medical Care Stock (DE0005785802): Quarterly earnings keep NYSE-listed shares in focus
Fresenius Medical Care's latest quarterly earnings highlight its continued profitability recovery, cost discipline, and exposure to the U.S. market. The company is actively optimizing its operations, product portfolio, and debt position to ensure sustainable growth, while navigating complex regulatory and economic environments. Investors are closely monitoring its performance, especially in relation to its NYSE-listed American depositary shares (FMS).
Hologic wins mammography patent infringement case against Siemens Healthineers
Hologic has won a patent infringement lawsuit against Siemens Healthineers in the European Unified Patent Court. The case involved Siemens' Mammomat B.brilliant breast tomosynthesis system and its "Flying Focal Spot" technology, which Hologic claimed to have invented. As a result, Siemens must remove all Mammomat B.brilliant systems from the market in Germany, France, and the Netherlands, destroy unsold units, and provide sales records dating back to August 2018.
Quality Beyond Compliance: Malik Khan on Protecting Patients and Powering Performance
Malik Khan, Corporate Vice President of Quality at Hologic, emphasizes that quality in the medical device industry has evolved beyond mere compliance to a strategic function that anticipates risk, improves performance, and protects patients. He advocates for embedding quality throughout the entire product lifecycle, from design to real-world use, fostering a culture of ownership and continuous improvement to ensure patient safety and product reliability. Khan highlights the shift towards proactive quality management through data-driven insights and AI, while also addressing new challenges like AI ethics, interoperability, and cybersecurity in medtech.
Hologic Inc Stock (US4364401012): S&P 500 exit keeps women’s health specialist on U.S. investors
Hologic Inc. remains a key focus for U.S. investors despite its exit from the S&P 500, trading on the Nasdaq under HOLX. The removal prompted discussions about index flows and valuation, highlighting the company's strong position in women's health diagnostics and imaging. Analysts are now re-evaluating Hologic's cash flow stability, recurring revenue model, and its specialized market niche compared to broader medical technology peers.
Software Loses Its Throne in the Leveraged Loan Market
Healthcare has surpassed software for the first time since 2015 as the leading sector in institutional loan issuance, while software loans have significantly declined. This shift is particularly evident in private equity-backed deals, where software's share in leveraged buyouts has dropped to its lowest in a decade, indicating a potential structural change driven by factors like AI disintermediation, valuation resets, and higher interest rates. Despite this, software remains the largest sector within the leveraged loan market, but with a shrinking universe due to fewer new buyouts and increased scrutiny from lenders.
Life After Breast Cancer: Why Treatment Decisions Are Becoming More Personal
This article discusses the increasing personalization of breast cancer treatment, particularly for hormone receptor-positive (HR+) cases, emphasizing the challenges of long-term endocrine therapy side effects. It highlights how genomic tests like the Breast Cancer Index® (BCI™) are crucial in guiding decisions on treatment duration, moving beyond a one-size-fits-all approach. The goal is to empower patients with information to make informed choices about their survivorship care based on individual tumor biology and recurrence risk.
Hologic, Inc. Analyst Forecast (HOLX)
This article provides an analyst forecast for Hologic, Inc. (HOLX), detailing current analyst consensus, average price targets, and distribution of ratings. It also includes forward analyst estimates for revenue, EBITDA, EPS, and net income, along with a chronological record of recent analyst grade changes and individual price targets.
T-Score & DXA: How Hologic Helped Define Bone Health
This article details how Hologic, particularly through the work of lead R&D scientist Tom Kelly, has advanced bone density testing with DXA technology. It highlights Kelly's co-invention of the T-score, which revolutionised osteoporosis diagnosis by comparing bone density to a young, healthy population, and discusses how DXA helps detect bone loss in women, especially around menopause or during certain breast cancer treatments. The piece also touches on future developments for DXA, including the role of AI in standardizing analyses.
LivaNova names Anne Liddy as chief legal officer
LivaNova PLC has appointed Anne Liddy as its new Chief Legal Officer, effective August 31, where she will oversee global legal and compliance functions and join the Executive Leadership Team. Liddy brings over 20 years of legal and compliance experience in the healthcare and life sciences sectors, previously serving as General Counsel at Hologic, Inc. This leadership addition comes as the medical technology company, valued at $4.05 billion, is trading near its 52-week high and is considered undervalued by InvestingPro analysis, following a strong Q1 2026 performance.
Top 10 Companies Driving Growth in Refurbished Medical Equipment Industry
The refurbished medical equipment industry is experiencing significant growth, projected to reach USD 35.74 billion by 2034 with a CAGR of 10.8%. This growth is driven by the modernization of healthcare, demand for cost-effective solutions, and technological innovations like AI-assisted models and remote diagnostics. Key players such as GE HealthCare, Siemens Healthineers, and Koninklijke Philips N.V. are leading this sector by offering sustainable, high-quality, and regulated refurbished devices.
Newly Published Data Suggests AI’s Potential to Help Streamline Mammography Reviews While Maintaining High Effectiveness in Finding Cancer
New research published in Radiology highlights the potential of Hologic’s 3DQuorum® imaging technology to streamline mammography reviews without sacrificing cancer detection rates. The study, led by Dr. Manisha Bahl, involved over 119,000 screening mammography exams and found no significant difference in cancer detection rates after implementing the AI-powered technology. This suggests the technology can help address radiologist shortages by improving workflow efficiency while maintaining high effectiveness in identifying breast cancer early.
Sanofi Chooses Snowflake to Accelerate its AI-Powered Drug Development
Sanofi has partnered with Snowflake to establish a new AI-powered blueprint for drug development, aiming to become the first biopharma company to operate at AI scale. Through Snowflake Cortex AI and Elementum, Sanofi is deploying AI agents across various departments, including R&D, manufacturing, and commercial, to unify data and accelerate decision-making. A prime example is "Concierge for Field," an AI agent that generates pre-call plans for sales representatives in seconds, streamlining operations that previously took hours.
Yakira Capital Takes New $6 Million Position In Allied Gold Corporation (NYSE: AAUC)
Yakira Capital Management, Inc. has acquired 195,710 shares in Allied Gold Corporation (NYSE: AAUC) for an estimated $5.91 million, as disclosed in an SEC filing. This new position represents 1.77% of Yakira Capital’s 13F assets under management. Allied Gold shares have significantly outperformed the S&P 500, with a 151.6% increase over the past year, and the company is preparing for its first gold production from the Kurmuk Project and is also set to be acquired by Zijin Gold.
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions
Hologic and Biotheranostics announced new data revealing the significant impact of the Breast Cancer Index (BCI) Test on guiding extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive breast cancer. The findings from the BCI Registry Study show that physician recommendations for extended endocrine therapy increased by over 30% for patients likely to benefit according to the BCI Test, and decreased by nearly 40% for those deemed unlikely to benefit. These results emphasize the BCI Test's role in personalizing care and are scheduled for presentation at the 2026 ASCO Annual Meeting.
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions
Hologic, Inc. and its subsidiary, Biotheranostics, Inc., will present new data at ASCO 2026 highlighting the clinical impact of the Breast Cancer Index® (BCI™) Test on extended endocrine therapy decisions for early-stage, HR+ breast cancer patients. The BCI Test results led to a significant increase in recommendations for extended therapy in likely beneficiaries and a decrease in those unlikely to benefit, demonstrating its effectiveness in personalizing patient care. These findings, derived from the BCI Registry Study, underscore the test's role in guiding physician treatment recommendations and managing recurrence risk.
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions
Hologic, Inc. announced new data on how its Breast Cancer Index® (BCI™) Test influences decisions for extended endocrine therapy in early-stage, hormone receptor-positive breast cancer patients. The findings from the BCI Registry Study show that physician recommendations for extended endocrine therapy significantly increased for patients identified as likely to benefit by the BCI Test and decreased for those unlikely to benefit. These results will be presented at the 2026 ASCO Annual Meeting, highlighting the BCI Test's role in personalizing treatment and improving informed decision-making.
OCONNOR, A Distinct Business Unit Of UBS ASSET MANAGEMENT AMERICAS (LLC) HOLX Holdings History
This article details the historical holdings of OCONNOR, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS (LLC), in Hologic Inc (HOLX). As of December 31, 2025, OCONNOR held 2.61 million shares of HOLX, valued at $194.05 million, representing 6.06% of its stock portfolio. The initial purchase occurred in Q4 2025, with an average acquisition price of $73.16 per share, leading to an estimated gain of $7.42 million or 3.90% on the investment based on the current HOLX price of $76.01.
Oura Ring now links sleep changes to Resmed sleep resources
Oura and Resmed have partnered to provide Oura Ring members in the U.S. with expanded access to sleep health education and care pathways. Oura Ring Gen3 and Ring 4 users can now access Resmed's educational tools, sleep assessments, and connect with independent healthcare providers to address sleep concerns, especially in light of the high rate of undiagnosed obstructive sleep apnea. This collaboration aims to help individuals better understand their sleep patterns and take informed action on potential issues.
Artivion Q1 2026 Earnings: Revenue Matches Estimates, EPS Misses by 35% - News and Statistics
Artivion's Q1 2026 earnings saw revenue of $116.3 million, matching analyst estimates, but adjusted EPS missed expectations by 35.1% at $0.08 versus $0.12. The company attributed the shortfall to weak stent graft sales and delays in AMDS starter set sales due to hospital procurement issues, leading to a downward revision in full-year revenue and EBITDA guidance. Analysts questioned management on the conservatism of the revised guidance and the impact of future PMA approval for AMDS.
Laura Friedman from California’s 30th District makes transactions in Hologic, Inc.
Laura Friedman, representative for California’s 30th congressional district, recently executed two transactions involving Hologic, Inc. She exchanged common stock for non-tradable contingent value rights and partially sold common stock due to the company's privatization. Both transactions, valued between $1,001 and $15,000, were processed via Fidelity Brokerage Services, LLC, and reported on May 3, 2026.
